Orthopaedics and cardiology groups start to improve in terms of sales per employee, but Covid test makers do better still.
Immunogen and Uniqure are also set for Pdufa conclusions.
A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.
But full data will be needed to confirm that sabizabulin is a real contender.
2021 rounds off with key FDA decisions for Argenx, Calliditas and Merck, while Novartis will be hoping for an early Leqvio verdict.
Big upcoming events include data from a trial of Pfizer’s oral antiviral Paxlovid in patients at risk of severe illness.